Other ‘Seismic shift’ as obesity overtakes cancer for R&D returns PharmaphorumFor the first time in its 16-year history, Deloitte's annual report on pharma R D returns sees obesity replace cancer as the largest driver.Metabolic & GLP-1Read full story pharminent May 5, 2026 (Last updated: May 5, 2026) Pharmaphorum For the first time in its 16-year history, Deloitte’s annual report on pharma R D returns sees obesity replace cancer as the largest driver. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Latus Bio secures $97m in funding to boost gene therapy accessNext: Lannett, Lanexa Biologics and Sunshine Lake secure FDA approval for Langlara Related Stories Other 225: An Interview With Craig Martin, Founder and CEO of the Orphan Therapeutics Accelerator pharminent May 18, 2026 Other Cellbxhealth partners with AdventHealth on CTCbased monitoring in two major cancer studies pharminent May 18, 2026 Other 223: An Interview With Dr. Antn Blatnik on the Molecular Mechanisms Driving Neuromuscular Disease pharminent May 4, 2026
